Pharma BD Deal Intelligence
A $4.5B carve-out that tripled Nycomed's scale to top-25 global pharma overnight, but the acquired pantoprazole franchise hit the generic cliff within a year, cutting Protonix sales from $1.9B to $1.1B—the real payoff came from Takeda's 2011 buyout of the whole group, not the Altana assets alone.
Transformed Nycomed into a top-25 global pharma overnight, but its core acquired asset (pantoprazole/Protonix) hit the generic cliff within a year of close; the visible PE payoff came from the 2011 Takeda exit of the whole group, not cleanly from the Altana assets alone.
Full analysis, sources & comparables →Setbacks for ciclesonide (Alvesco) and roflumilast (Daxas) in the US 'took some of the lustre off' Altana's near-term pipeline, raising questions about…
Shareholder activists argued Altana management had under-invested in the pharma business and failed to develop successor products before pantoprazole's patent…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
EUR 4.5B / ~$5.7B. Acquired Jan 1, 2007 effective; deal announced 2006 closed early 2007. Pantoprazole, respiratory franchise. Source: Pharma Times, C&EN, PitchBook.
Transformed Nycomed into a top-25 global pharma overnight, but its core acquired asset (pantoprazole/Protonix) hit the generic cliff within a year of close; the visible PE payoff came from the 2011 Takeda exit of the whole group, not cleanly from the Altana assets alone.
Assessment window: 15yr post-close.
$1.8B Pantoprazole (Pantozol/Protonix) global sales pre-deal
Proton pump inhibitors (PPIs) like pantoprazole reduce gastric acid by irreversibly blocking H+/K+ ATPase in parietal cells, treating GERD, peptic ulcers, and Zollinger-Ellison syndrome. COPD is a progressive, smoking-related airflow obstruction; asthma is reversible airway inflammation — both treated with inhaled corticosteroids and bronchodilators.
In 2006, the PPI class was a $25B+ market dominated by AstraZeneca's Nexium (esomeprazole, the follow-on to Prilosec/omeprazole), Takeda's Prevacid (lansoprazole), and Eisai/Janssen's AcipHex (rabeprazole). Altana's Pantoprazole — sold as Pantozol in Europe and partnered with Wyeth as Protonix in the US — generated $1.8B in 2005 sales but faced Protonix LOE in early 2010 and European generics by 2009. In COPD/asthma, the dominant franchises were GSK's Advair/Seretide (fluticasone/salmeterol) and AstraZeneca's Symbicort (budesonide/formoterol). Altana's Alvesco (ciclesonide) inhaled corticosteroid had launched but faced steep competition; Daxas (roflumilast), a first-in-class oral PDE-4 inhibitor for severe COPD, was the key pipeline asset but had been hit by Pfizer terminating its partnership in 2005 and US regulatory delays after the FDA's 2003 advisory rejection of GSK's PDE-4 cilomilast. Nycomed paid EUR 4.5B (~$5.7B) at an EV/EBITDA of ~6.3x — analysts called it a 'bet on resolving Altana's pipeline challenges' given the thin late-stage pipeline beyond pantoprazole. Daxas was ultimately approved in EU 2010 and US 2011 (Daliresp), validating the bet shortly before Takeda acquired Nycomed in 2011 for EUR 9.6B. Sources: https://pharmatimes.com/news/nycomed_buys_altanas_drug_unit_for_4-5bn_euros_997184/ ; https://www.pharmiweb.com/article/double-trouble-hits-altana-respiratory-pipeline
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Nycomed / Altana Pharma AG (this deal) | 2007 | $4.5B | 58 |
| Nycomed / Altana Pharma AG | 2006 | $5.7B | 59 |
| Nycomed / Bradley Pharmaceuticals | 2007 | $346M | 48 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Shire plc / New River Pharmaceuticals Inc. | 2007 | $2.6B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2007 deals · Nycomed deals